Free Float 83,15 %
Shares Float 4,28 M
Shares Outstanding 5,15 M
MEDSIS PHARMA SA EO 2,-
Share · FR0010844464 · A2QN88 (XFRA)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of MEDSIS PHARMA SA EO 2,-
No Price
Share Float & Liquidity
Company Profile for MEDSIS PHARMA SA EO 2,- Share
Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.
Company Data
Name MEDSIS PHARMA SA EO 2,-
Company Medesis Pharma S.A.
Website
https://www.medesispharma.com
Primary Exchange 
Frankfurt
Frankfurt
WKN A2QN88
ISIN FR0010844464
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Jean-Claude Maurel MHB
Country France
Currency EUR
Employees 0,0 T
Address L'Orée des Mas, 34670 Montpellier
IPO Date 2021-02-12
Ticker Symbols
| Name | Symbol |
|---|---|
| Frankfurt | 76D.F |
| Paris | ALMDP.PA |
More Shares
Investors who hold MEDSIS PHARMA SA EO 2,- also have the following shares in their portfolio:
